Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

CRVS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows in line with its trailing trend

Q1 FY2026 depreciation & amortization of $29K rose 31.8% year over year, behind the +33.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at -34.1% a year.

Context

  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +31.8% toward the trailing-twelve-month pace of +33.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$29K+11.5% QoQ
Last fiscal yearDec 2025
$105K+23.5% YoY
LTMMar 2026
$112K+33.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.8%——
1 year+23.5%——
3-year CAGR-34.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
105K USD
Year-over-year change
+23.5%
4-year CAGR
-30.9%

Depreciation & Amortization vs competitors

How CRVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +33.3% is the 2nd highest of 8, against a peer median of -21.9%.
  • Over three fiscal years its annual growth of -34.1% compares with a peer median of -15.4%.
CRVS Competitors
Depreciation & Amortization for CRVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$10M USD+0.0%+18.6%8.5%
MGNXMacroGenics, Inc.LTM Mar 2026$7.09M USD-5.1%-15.4%4.5%
IPHAInnate Pharma S.A.FY2025€5.09M EUR+155.3%-51.8%182.7%
CHRSCoherus Oncology, Inc.LTM Mar 2026$3.76M USD-21.9%+2.0%8.0%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.24M USD-26.3%-17.4%3.5%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$1.12M USD-32.0%-8.2%—
ADAGAdagene Inc.LTM Jun 2024$931.31K USD—-25.6%114.2%
NKTRNektar TherapeuticsLTM Jun 2026$537K USD-72.7%-56.2%1.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$112K USD+33.3%-34.1%—
CGENCompugen Ltd.LTM Mar 2026$0 USD—-0.5%0.0%
Peer median (excluding CRVS) —-21.9%-15.4%6.3%

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000105K
Gross Profit0000(105K)
Gross Margin—————
Research & Development29.12M24.47M16.53M19.39M33.72M
Selling, General & Admin9.52M8.1M6.88M8.16M9.25M
Operating Expenses38.63M32.57M23.41M27.55M42.87M
Depreciation & Amortization460K367K151K85K105K
EBITDA(42.77M)(40.94M)(26.88M)(62.21M)(15.18M)
EBITDA Margin—————
Operating Income(38.63M)(32.57M)(23.41M)(27.55M)(42.97M)
Operating Margin—————
Interest Income0654K1.58M1.82M2.51M
Interest Expense15K0000
Other Income / Expenses(4.61M)(8.74M)(3.62M)(34.75M)27.69M
Income Before Tax(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Net Margin—————
EPS (Basic)(1.03)(0.89)(0.56)(1.02)(0.19)
EPS (Diluted)(1.03)(0.89)(0.56)(1.02)(0.53)
Weighted Avg Shares41.85M46.55M48.03M60.99M78.96M
Weighted Avg Shares (Diluted)41.85M46.55M48.03M60.99M79.74M

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.